William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, explain how the COVID-19 pandemic has had an impact on the seasonality of respiratory syncytial virus (RSV).
William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, explain how the COVID-19 pandemic has had an impact on the seasonality of respiratory syncytial virus (RSV).
Transcript
How has the COVID-19 pandemic impacted the normal seasonality of respiratory syncytial virus?
Stinchfield: The COVID-19 pandemic has disrupted a lot of things, including other viruses, some of which have had to take a backseat to this virus. RSV season, as we typically see it in the fall and winter, was definitely disrupted. At the beginning of the pandemic, we saw some coinfections in children—both RSV and SARS-CoV-2, or influenza [and] SARS-CoV-2, a little bit of influenza and RSV. The second winter, though, we really didn't see much RSV and then, very strangely, RSV reemerged in the summer unexpectedly and with a vengeance. The pediatric population has quieted down, and now when it's supposed to be high right now, it's really not as much of a factor.
Schaffner: And that's been true largely across the country, because it's happened exactly as Patsy's described in Minnesota [and] that's exactly what's happened here in Tennessee. RSV has come early, disappeared early, or almost disappeared early. We're looking forward to reviewing our data to see how many coinfections we will find of both RSV and COVID at the same time. How frequent is it? Can we distinguish these patients from others? Do they produce more severe disease when they are present at the same time? Those are questions that are still unanswered.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More